SUIC Worldwide acquires 51% of Vision Renu Corporation for 30 million shares
SUIC Worldwide Holdings Ltd. completed an acquisition of a 51% stake in Vision Renu Corporation on July 10, 2026, issuing 30,000,000 shares of SUIC common stock to Vision Renu shareholders. The exchange shares represent approximately 35% of SUIC's total outstanding shares on a fully-diluted basis, and Vision Renu will become a wholly-owned subsidiary of SUIC. The transaction's board and management changes took effect at closing, with Chen King Te elected as Chairman and CEO, and Shan Hua Peng as CFO, replacing departing directors and officers.
Key facts
- 51% stake in Vision Renu Corporation acquired for 30,000,000 shares of SUIC common stock
- Exchange shares represent approximately 35% of SUIC's total outstanding shares on a fully-diluted basis
- Vision Renu will be a wholly-owned subsidiary of SUIC
- Closing date: July 10, 2026
- Chen King Te elected as Chairman, director and Chief Executive Officer
- Shan Hua Peng elected as director and Chief Financial Officer
- Harriette Lo, Han Wei Wang, and Yee Wei Tan resigned as directors and officers
- Vision Renu has 7 full-time employees
- Vision Renu develops scleral micro-ablation laser system for presbyopia and transcranial magnetic stimulation device for depression
Why it matters
The acquisition grants Vision Renu shareholders controlling influence over SUIC through their 35% fully-diluted ownership stake and seats on the board, fundamentally shifting control of the company and its strategic direction toward medical device development in optometry and psychiatric care.
Share
Derived from 8-K filed 2026-07-10. Not investment advice. View the source filing on SEC.gov →